NCT00857896

Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years

An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 8 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.

Conditions

• Overactive Bladder
• Neurogenic Detrusor Overactivity

Interventions

Type	Name	Description
DRUG	Fesoterodine	4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8

Timeline

• Start date: 2009-03-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2009-03-09
• Last updated: 2011-11-24
• Results posted: 2011-11-17

Locations

9 sites across 1 country: United States